Provider Order Form rev. 4/10/2022

Soliris (Eculizumab)



PATIENT INFORMATION	Referral Status (check one):	□ New Referral	Updated Order	Order Renewal		
Patient Name:			DOB:			
NKDA 🗆 Allergies:	Weight	Please specify	r⊡lbs □kg	Height:		
Patient Status (<i>check one</i>): New to Therapy Continuing Therapy	/ Last Treatment Dat	e:	Next Due Date:			
ICD-10 code (required): ICD-10	description:	on:				
REQUIRED: Demographics & Most Recent: H&P, clin past tried and/or failed therapies, intoleran PRESCRIPTION				iny		
NURSING	PRE-MEDICATIO	N ORDERS				
Provide nursing care per AdaptIV Infusion Nursing Procedures, inc reaction management and post-procedure observation	5	 acetaminophen (Tylenol) 500mg 650mg 1000mg PO cetirizine (Zyrtec) 10mg PO loratadine (Claritin) 10mg PO diphenhydramine (Benadryl) 25mg 50mg PO 1V 				
Meningococcal vaccination (both conjugate and serogroup B) are required prior to initiating Soliris infusions.	🗌 loratadine (C		25mal □ 50mal			

MENINGITIS VACCINE - Patients are required to receive first dose of both Conjugate and serogroup b vaccines prior to initiating Soliris.

Unless otherwise noted, vaccines will be given 2 weeks prior to starting Soliris infusion. AdaptIV Infusion will schedule the patient for vaccine visit followed by Soliris two weeks later. If urgent Soliris therapy is indicated in an unvaccinated patient, AdaptIV Infusion will administer meningococcal vaccine(s) as soon as possible including same day as Soliris infusion. Additionally, provider must prescribe patients with 2 weeks of antibacterial drug prophylaxis.

\Box Check here if this is an **urgent** start.

ADAPTIV INFUSION WILL ADMINISTER BOTH VACCINES AS OUTLINED BELOW. Meningococcal conjugate (MenACWY) vaccine

[Patient will be given either Menactra or Menveo vaccine based on availability and will receive **two doses separated by at least eight weeks.** Menactra and Menveo are not interchangeable and patient will receive same product for all doses in a series.]

Serogroup B Meningococcal (MenB) vaccine

[Patient will be given Bexsero or Trumenba vaccine based on availability and will receive either the two-dose series Bexsero at least one month apart or three-dose series Trumenba at 0, 1-2, and 6 months. Bexsero and Trumenba are not interchangeable and patient will receive same product for all doses in a series.]

Monitor the patient for at least one hour following completion of the infusion for signs or symptoms of an infusion reaction.

Dose: _____ Frequency:

THERAPY ADMINISTRATION

Eculizumab (Soliris) in 0.9% sodium chloride, IV infusion

- **Dose: Induction:** (Choose one. If patient has already completed induction dose, proceed to maintenance dose.)
 - 600mg weekly for the first four weeks followed by 900mg for the fifth dose one week later, then 900mg two weeks later

Route:

- 900mg weekly for the first four weeks followed by 1200mg for the fifth dose one week later, then 1200mg two weeks later
- Dose: Maintenance: (Choose one)
 900mg every two weeks / 1200mg every two weeks
- Dilute with 0.9% NS to a final concentration of 5mg/ml. (300mg doses final volume 60ml, 600mg doses final volume 120ml, 900mg doses final volume 180ml, 1200mg doses final volume 240ml.)
- Infuse over 35 minutes in adults and 1-4 hours in pediatric patients
- $\hfill\square$ Flush with 0.9% sodium chloride at infusion completion
- □ Patient is required to stay for 60 min. observation

Please continue to next page.

adaptIV infusion ____/___/____

_____/____/____ Today's Date

Patient Name (Print)

SPECIAL INSTRUCTIONS

PROVIDER INFORMATION

Referral Coordinator Name: Ordering Provider:		Referral Coordinator Email:			
		Provider NPI:			
Referring Practice Name:		Phone:	Fax:		
Practice Address:		City:	State:	Zip Code:	
Provider Name (Print)	Provider Signature			Date	